Status: Recruiting
Study of Olutasidenib and Temozolomide in HGG
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
Participants needed: 60
Trial details
Phase: Phase 2Age: 12-39Biological sex: AllType: InterventionalSponsor: Rigel PharmaceuticalsUpdated: Jun 12, 2026Locations: 20
Eligibility criteria
Stratum A: Patients with localized, intracranial, non-pontine, and non-thalamic... [+23]
Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entere... [+26]